Expression Profiling of microRNA Following Administration of Dexmedetomidine

NCT ID: NCT03213743

Last Updated: 2017-07-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-19
• Study Completion Date: 2017-06-21

Brief Summary

The purpose of the study is to find out the differential expression profiling of microRNA before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microRNA.

Detailed Description

Background and objective: The use of dexmedetomidine may have benefits on the clinical outcomes of cardiac surgery. MicroRNAs are non-coding RNA sequences that act as regulators of gene expression. Investigators conduct a study to determine the role of microRNAs in cardioprotection mediated by dexmedetomidine.

Methods: In this study 3 patients were selected. The blood sample were taken before administration of dexmedetomidine.Investigators infused loading dose of dexmedetomidine for 10 minutes and maintaining dese of dexmedetomidine for 20 minutes.Thirty minutes after the administration, another blood samples were taken and stored in the liquid nitrogen and both the samples were marked. Those sample were analyzed for differentially expressed microRNA with Exiqon miRNA Array.

Conditions

Coronary Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

before dexmedetomidine

We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.

Group Type: OTHER

Dexmedetomidine Injection

Intervention Type: DRUG

Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.

Interventions

Dexmedetomidine Injection

Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.

Intervention Type: DRUG

Other Intervention Names

Dex group

Eligibility Criteria

Inclusion Criteria

• The patients without arrithmia will undergo procedure.

Exclusion Criteria

• The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

First Affiliated Hospital of Kunming Medical University

OTHER

Sponsor Role: lead

Responsible Party

Jinqiao Qian

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jinqiao Qian, Ph.D

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital of Kunming Medical University

Locations

Jinqiao Qian

Kunming, Yunnan, China

Countries

China

Other Identifiers

1stKunmingMCQJQ

Identifier Type: -

Identifier Source: org_study_id